|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
A Diverse Technique for Antibody Screening of Clinical Samples
a Pathogenetics Unit, Laboratory of Pathology and Urologic Oncology Branch, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4605, USA b Tumor Angiogenesis Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4605, USA c SAIC Frederick Inc. Frederick, Maryland, USA
Key Words: layered peptide array • multiplex • high-throughput • ELISA • immunohistochemistry
Address for correspondence: Michael Emmert-Buck, Advanced Technology Center, Center for Cancer Research, National Cancer Institute, 8717 Grovemont Circle, Bethesda, MD 20892-4605. Voice: (301)-496-2912; fax: (301)-594-7582. buckm{at}mail.nih.gov
The layered peptide array (LPA) is a recently developed technique designed to measure antibody levels in a multiplex, high-throughput manner. LPAs can assess antibody presence either in fluid samples or from tissues while maintaining the two-dimensional orientation of the life science platform. In this manuscript, we evaluated and assessed the performance of the LPA platform, focusing on throughput capability, sensitivity, and specificity of the assay in several different systems.
|
 |
 |
